Patents Assigned to Tufts Medical Center
-
Patent number: 10766965Abstract: The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.Type: GrantFiled: May 20, 2016Date of Patent: September 8, 2020Assignees: JANSSEN BIOTECH, INC., TUFTS MEDICAL CENTER, INC.Inventors: Chakra Chaulagain, Raymond Comenzo, Parul Doshi, Xun Ma, Amy Sasser
-
Publication number: 20200277382Abstract: The present invention relates to bispecific antibody constructs that specifically bind both integrin alpha-V and integrin ?5 (e.g., ?5?1) and methods of making and using those constructs to treat cancer or Activated Fibroblasts other pathological conditions involving these integrins.Type: ApplicationFiled: October 30, 2018Publication date: September 3, 2020Applicant: Tufts Medical Center, Inc.Inventor: Paul Mathew
-
Patent number: 10758715Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: GrantFiled: August 15, 2016Date of Patent: September 1, 2020Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Patent number: 10703820Abstract: Endoglin has been identified to play a functional role as a regulator of TGF?1 signaling, particular in TGF?1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGF?1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.Type: GrantFiled: January 23, 2019Date of Patent: July 7, 2020Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Patent number: 10596357Abstract: Implantable shunt devices and methods for draining cerebrospinal fluid from a patient's subarachnoid space include a shunt having opposed first and second ends, the second end being constructed to penetrate a wall of a sigmoid, transverse, straight, or sagittal sinus of the patient, a one-way valve, a hollow passageway extending between the second end and the one-way valve such that cerebrospinal fluid can be drained through the second end and out through the valve, and a mechanism coupled to the shunt and configured to anchor the shunt at a desired location proximal to the subarachnoid space.Type: GrantFiled: April 6, 2017Date of Patent: March 24, 2020Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek
-
Publication number: 20200062771Abstract: The present disclosure relates to derivatized agelastatin compounds and methods for the treatment, prevention, or delay of cancer, comprising administering a therapeutically effect amount of the derivatized agelastatin compounds, a pharmaceutically acceptable salt thereof, or a composition thereof to a subject in need thereof. Methods for making the derivatized agelastatin compounds are also provided.Type: ApplicationFiled: May 11, 2018Publication date: February 27, 2020Applicants: Massachusetts Institute of Technology, Tufts Medical Center, Inc.Inventors: Mohammad Movassaghi, Alyssa H. Antropow, Rachel J. Buchsbaum, Kun Xu Xu
-
Publication number: 20190255302Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: ApplicationFiled: May 2, 2019Publication date: August 22, 2019Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 10279152Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: GrantFiled: July 6, 2016Date of Patent: May 7, 2019Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Publication number: 20190126014Abstract: Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.Type: ApplicationFiled: October 23, 2018Publication date: May 2, 2019Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 10258284Abstract: An implant sized and shaped to be endovascularly delivered to the middle meningeal artery includes a carrier that carries a payload between first and second ends thereof. An anchor mechanism associated with the implant transitions into a swollen state in response to exposure to bodily fluids. In the swollen state, said anchor mechanism anchors the implant to the middle meningeal artery. Before or during the transition, the anchor mechanism permits endovascular delivery of the implant to the middle meningeal artery.Type: GrantFiled: April 5, 2018Date of Patent: April 16, 2019Assignee: Tufts Medical center, Inc.Inventors: Adel M. Malek, Carl Heilman
-
Patent number: 10233219Abstract: The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.Type: GrantFiled: March 13, 2014Date of Patent: March 19, 2019Assignees: Tufts Medical Center, Trustees of Tufts College, On Target Therapeutics LLCInventors: Charles Cohen, Krishna Kumar, Jamie Raudensky Doyle, Alan S. Kopin
-
Patent number: 10214590Abstract: Endoglin has been identified to play a functional role as a regulator of TGF?1 signaling, particular in TGF?1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGF?1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.Type: GrantFiled: September 18, 2014Date of Patent: February 26, 2019Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Publication number: 20190055279Abstract: The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.Type: ApplicationFiled: October 28, 2016Publication date: February 21, 2019Applicants: TUFTS UNIVERSITY, TUFTS MEDICAL CENTERInventors: KRISHNA KUMAR, VITTORIO MONTANARI, MARTIN BEINBORN, VENKATA RAMAN
-
Publication number: 20190000885Abstract: Aspects of the technology disclosed herein generally (and in part) relates to use of Angiogenin (ANG) for increasing hematopoietic reconstitution of in vivo hematopoietic cells and transplanted hematopoietic cells. Provided herein are methods and compositions useful in treatment of diseases characterized by decreased levels of hematopoietic cells, decreased levels of hematopoietic reconstitution, blood cell deficiency and prevention and treatment of radiation injury. One aspect relates to angiogenin treated hematopoietic cell compositions and methods of their use in stem cell transplantation. Treatment of hematopoietic cells with angiogenin enhances quiescence and reduces proliferative capacity of primitive hematopoietic stem cells while increasing proliferation of myeloid restricted progenitor cells. Another aspect relates to use of ANG in prophylactic and therapeutic treatment methods for radiation injury.Type: ApplicationFiled: November 29, 2016Publication date: January 3, 2019Applicants: THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC., TRUSTEES OF TUFTS COLLEGE, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: David SCADDEN, Peter KHARCHENKO, Lev SILBERSTEIN, Guo-fu HU, Kevin GONCALVES
-
Patent number: 10112036Abstract: An endovascular implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space includes a shunt having opposed first and second ends, a one-way valve located at the first end of the shunt, a helical tip disposed at the second end, and a hollow passageway extending between the helical tip and one-way valve. The helical tip is constructed to penetrate a patient's sinus wall. Cerebrospinal fluid drains through the helical tip and out through the valve.Type: GrantFiled: October 22, 2015Date of Patent: October 30, 2018Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek
-
Patent number: 10106834Abstract: Methods for the diagnosis and treatment of B cell Acute Lymphoblastic Leukemia (B-ALL), based in part on the detection and/or inhibition of Focal Adhesion Kinase (FAK), e.g., phosphorylated FAK (pFAK).Type: GrantFiled: October 9, 2014Date of Patent: October 23, 2018Assignees: The General Hospital Corporation, Tufts Medical Center, Inc.Inventors: Katia Georgopoulos, Richard A. Etten, Ila Joshi
-
Publication number: 20180243541Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: ApplicationFiled: August 15, 2016Publication date: August 30, 2018Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 9878054Abstract: In certain embodiments, this disclosure relates to pharmaceutical formulations for polypeptide and lipophilic moiety conjugates suitable for injection into humans and other animals and methods of preparation. In certain embodiments, the disclosure relates to a method of preparing the formulation comprising lyophilizing, solubilizing in ammonium acetate, filtering to create mono-disperse particles, re-lyophilizing, and solubilizing the micelles in a dextrose solution for injection.Type: GrantFiled: May 17, 2013Date of Patent: January 30, 2018Assignee: Tufts Medical Center, Inc.Inventor: Athan Kuliopulos
-
Patent number: 9737696Abstract: Implantable shunt devices and methods for draining cerebrospinal fluid from a patient's subarachnoid space include a shunt having opposed first and second ends, the second end being constructed to penetrate a wall of a sigmoid, transverse, straight, or sagittal sinus of the patient, a one-way valve, a hollow passageway extending between the second end and the one-way valve such that cerebrospinal fluid can be drained through the second end and out through the valve, and a mechanism coupled to the shunt and configured to anchor the shunt at a desired location proximal to the subarachnoid space.Type: GrantFiled: January 14, 2015Date of Patent: August 22, 2017Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek
-
Patent number: 9737697Abstract: An endovascular implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space includes a shunt having opposed first and second ends, a one-way valve located at the first end of the shunt, a tip disposed at the second end, and a hollow passageway extending between the tip and one-way valve. The tip is constructed to penetrate a patient's sinus wall. Cerebrospinal fluid drains through the tip and out through the valve.Type: GrantFiled: October 14, 2016Date of Patent: August 22, 2017Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek